Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAZAmed is a proprietary formulation of procaine developed by **inflamed pharma GmbH**, a portfolio company of **Xlife Sciences**. The product utilizes the **ProcCluster** technology, which creates a highly bioavailable "cluster" form of procaine hydrochloride. While procaine is traditionally known as a local anesthetic, DAZAmed is designed to leverage its systemic and local anti-inflammatory properties for applications in dermatology and the treatment of inflammatory conditions. Additionally, the product has been positioned as an antiseptic and disinfectant. The ProcCluster formulation is intended to improve the stability and membrane permeability of the active ingredient compared to standard procaine solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DAZAmed.